Phosphaturic Mesenchymal Tumor

References

1. 1.↵
   2. Lee J,
   3. Folpe AL

   . Phosphaturic mesenchymal tumor. In: Editorial Board. WHO Classification of Tumours: Soft Tissue and Bone Tumours. International Agency for Research on Cancer; 2020
2. 2.↵
   2. Bahrami A,
   3. Weiss SW,
   4. Montgomery E, et al

   . RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor-induced osteomalacia. Am J Surg Pathol 2009;33:1348–54 doi:10.1097/PAS.0b013e3181aa2311 pmid:19609206

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Folpe AL,
   3. Fanburg-Smith JC,
   4. Billings SD, et al

   . Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 2004;28:1–30 doi:10.1097/00000478-200401000-00001 pmid:14707860

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Kumar S,
   3. Shah R,
   4. Patil V, et al

   . Tumor-induced rickets-osteomalacia: an enigma. J Pediatr Endocrinol Metab 2020 July 20. [Epub ahead of print] doi:10.1515/jpem-2020-0079 pmid:32681779

   CrossRefPubMed
5. 5.↵
   2. Honda R,
   3. Kawabata Y,
   4. Ito S, et al

   . Phosphaturic mesenchymal tumor, mixed connective tissue type, non-phosphaturic variant: report of a case and review of 32 cases from the Japanese published work. J Dermatol 2014;41:845–49 doi:10.1111/1346-8138.12602 pmid:25182295

   CrossRefPubMed
6. 6.↵
   2. Wu H,
   3. Bui MM,
   4. Zhou L, et al

   . Phosphaturic mesenchymal tumor with an admixture of epithelial and mesenchymal elements in the jaws: clinicopathological and immunohistochemical analysis of 22 cases with literature review. Mod Pathol 2019;32:189–204 doi:10.1038/s41379-018-0100-0 pmid:30206408

   CrossRefPubMed
7. 7.↵
   2. Hodgson SF,
   3. Clarke BL,
   4. Tebben PJ, et al

   . Oncogenic osteomalacia: localization of underlying peripheral mesenchymal tumors with use of Tc 99m sestamibi scintigraphy. Endocr Pract 2006;12:35–42 doi:10.4158/EP.12.1.35 pmid:16524861

   CrossRefPubMed
8. 8.↵
   2. Oyama N,
   3. Kojima-Ishii K,
   4. Toda N, et al

   . Malignant transformation of phosphaturic mesenchymal tumor: a case report and literature review. Clin Pediatr Endocrinol 2020;29:69–75 doi:10.1297/cpe.29.69 pmid:32313375

   CrossRefPubMed
9. 9.↵
   2. Morimoto T,
   3. Takenaka S,
   4. Hashimoto N, et al

   . Malignant phosphaturic mesenchymal tumor of the pelvis: a report of two cases. Oncol Lett 2014;8:67–71 doi:10.3892/ol.2014.2081 pmid:24959220

   CrossRefPubMed
10. 10.↵
    2. Qiu S,
    3. Cao LL,
    4. Qiu Y, et al

    . Malignant phosphaturic mesenchymal tumor with pulmonary metastasis: a case report. Medicine (Baltimore) 2017;96:e6750 doi:10.1097/MD.0000000000006750 pmid:28445300

    CrossRefPubMed
11. 11.↵
    2. Ghorbani-Aghbolaghi A,
    3. Darrow MA,
    4. Wang T

    . Phosphaturic mesenchymal tumor (PMT): exceptionally rare disease, yet crucial not to miss. Autops Case Rep 2017;7:32–37 doi:10.4322/acr.2017.031 pmid:28445300

    CrossRefPubMed
12. 12.↵
    2. Pelo S,
    3. Gasparini G,
    4. Garagiola U, et al

    . Phosphaturic mesenchymal tumor, an unusual localization in head and neck. J Surg Case Rep 2018;2018:rjy091 doi:10.1093/jscr/rjy091 pmid:29942463

    CrossRefPubMed
13. 13.↵
    2. Shiba E,
    3. Matsuyama A,
    4. Shibuya R, et al

    . Immunohistochemical and molecular detection of the expression of FGF23 in phosphaturic mesenchymal tumors including the non-phosphaturic variant. Diagn Pathol 2016;11:26 doi:10.1186/s13000-016-0477-3 pmid:26956379

    CrossRefPubMed
14. 14.↵
    2. Winters R,
    3. Bihlmeyer S,
    4. McCahill L, et al

    . Phosphaturic mesenchymal tumour-mixed connective tissue variant without oncogenic osteomalacia. J Clin Pathol 2009;62:760–61 doi:10.1136/jcp.2008.055996 pmid:19638551

    Abstract/FREE Full Text
15. 15.↵
    2. Folpe AL

    . Phosphaturic mesenchymal tumors: a review and update. Semin Diagn Pathol 2019;36:260–68 doi:10.1053/j.semdp.2019.07.002 pmid:31301876

    CrossRefPubMed
16. 16.↵
    2. Adnan Z,
    3. Nikomarov D,
    4. Weiler-Sagie M, et al

    . N. Phosphaturic mesenchymal tumors among elderly patients: a case report and review of literature. Endocrinol Diabetes Metab Case Rep 2019;2019:18–139 doi:10.1530/EDM-18-01396] pmid:31051470

    CrossRefPubMed
17. 17.↵
    2. Drezner MK

    . Tumor-induced osteomalacia. Rev Endocr Metab Disord 2001;2:175–86 doi:10.1023/A:1010006811394 pmid:11705323

    CrossRefPubMed
18. 18.↵
    2. Cho SI,
    3. Do NY,
    4. Yu SW, et al

    . Nasal hemangiopericytoma causing oncogenic osteomalacia. Clin Exp Otorhinolaryngol 2012;5:173–76 doi:10.3342/ceo.2012.5.3.173 pmid:22977716

    CrossRefPubMed
19. 19.↵
    2. Edmister KA,
    3. Sundaram M

    . Oncogenic osteomalacia. Semin Musculoskelet Radiol 2002;6:191–96 doi:10.1055/s-2002-36716 pmid:12541196

    CrossRefPubMed
20. 20.↵
    2. Jagtap VS,
    3. Sarathi V,
    4. Lila AR, et al

    . Tumor-induced osteomalacia: a single center experience. Endocr Pract 2011;17:177–84 doi:10.4158/EP10151.OR pmid:20713341

    CrossRefPubMed
21. 21.↵
    2. Liu S,
    3. Zhou X,
    4. Song A, et al

    . Successful treatment of tumor-induced osteomalacia causing by phosphaturic mesenchymal tumor of the foot. Medicine (Baltimore) 2019;98:e16296 doi:10.1097/MD.0000000000016296 pmid:31277164

    CrossRefPubMed
22. 22.↵
    2. Broski SM,
    3. Folpe AL,
    4. Wenger DE

    . Imaging features of phosphaturic mesenchymal tumors. Skeletal Radiol 2019;48:119–27 doi:10.1007/s00256-018-3014-5 pmid:29987349

    CrossRefPubMed
23. 23.↵
    2. El-Maouche D,
    3. Sadowski SM,
    4. Papadakis GZ, et al

    . ⁶⁸Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J Clin Endocrinol Metab 2016;101:3575–81 doi:10.1210/jc.2016-2052 pmid:27533306

    CrossRefPubMed
24. 24.↵
    2. Ha S,
    3. Park S,
    4. Kim H, et al

    . Successful localization using ⁶⁸Ga-DOTATOC PET/CT of a phosphaturic mesenchymal tumor causing osteomalacia in a patient with concurrent follicular lymphoma. Nucl Med Mol Imaging 2018;52:462–67 doi:10.1007/s13139-018-0546-5 pmid:30538778

    CrossRefPubMed
25. 25.↵
    2. Kawthalkar AS,
    3. Janu AK,
    4. Deshpande MS, et al

    . Phosphaturic mesenchymal tumors from head to toe: imaging findings and role of the radiologist in diagnosing tumor-induced osteomalacia. Indian J Orthop 2020;54:215–23 doi:10.1007/s43465-019-00005-5 pmid:32257040

    CrossRefPubMed
26. 26.↵
    2. Walsh EM,
    3. Jacob J,
    4. Lucas DR, et al

    . Phosphaturic mesenchymal tumor of the cerebellopontine angle. JAMA Otolaryngol Head Neck Surg 2019;145:287–88 doi:10.1001/jamaoto.2018.4045 pmid:30703204

    CrossRefPubMed
27. 27.↵
    2. Richardson AL,
    3. Richardson OK

    . Phosphaturic mesenchymal tumor: case report. Radiol Case Rep 2019;14:1518–24 doi:10.1016/j.radcr.2019.09.027 pmid:31681451

    CrossRefPubMed
28. 28.↵
    2. Kane SV,
    3. Kakkar A,
    4. Oza N, et al

    . Phosphaturic mesenchymal tumor of the nasal cavity and paranasal sinuses: a clinical curiosity presenting a diagnostic challenge. Auris Nasus Larynx 2018;45:377–83 doi:10.1016/j.anl.2017.05.006 pmid:28579442

    CrossRefPubMed
29. 29.↵
    2. Radaideh AR,
    3. Jaradat D,
    4. Abu-Kalaf MM, et al

    . Resolution of severe oncogenic hypophosphatemic osteomalacia after resection of a deeply located soft-tissue tumour. Curr Oncol 2009;16:87–90 doi:10.3747/co.v16i5.412 pmid:19862367

    CrossRefPubMed
30. 30.↵
    2. Horng JC,
    3. Van Eperen E,
    4. Tutton S, et al

    . Persistent phosphaturic mesenchymal tumor causing tumor-induced osteomalacia treated with image-guided ablation. Osteoporos Int J Int 2021;32:1895–98 doi:10.1007/s00198-020-05795-1 pmid:33655402

    CrossRefPubMed
31. 31.↵
    2. Brandi ML,
    3. Clunie GP,
    4. Houillier P, et al

    . Challenges in the management of tumor-induced osteomalacia (TIO). Bone 2021;152:116064 doi:10.1016/j.bone.2021.116064 pmid:34147708

    CrossRefPubMed